CASC3 and plasma cell myeloma: In vivo, BP-Btz more effectively reduced tumor burden and bone loss than Btz in the 5TGM1 mouse model of multiple myeloma; additionally, BP-Btz generated significantly less in terms of systemic adverse effects, such as thrombocytopenia, compared with Btz alone [18].